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SYSTEMATIC REVIEW
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ABSTRACT
Background: The development of therapeutics is often charac-
terized by promising animal research that fails to translate into clin-
ical efficacy; this holds for the development of gene therapy in
glioma.We tested the hypothesis that this is because of limitations
in the internal and external validity of studies reporting the use of
gene therapy in experimental glioma.
Method:Wesystematically identified studies testing gene therapy
in rodent glioma models by searching three online databases. The
number of animals treated andmedian survival were extracted and
studies graded using a quality checklist. We calculated median sur-
vival ratios and used random effects meta-analysis to estimate effi-
cacy.We explored effects of study design and quality and searched
for evidence of publication bias.
Results: We identified 193 publications using gene therapy in
experimental glioma, including 6,366 animals. Overall, gene
therapy improved median survival by a factor of 1.60 (95% CI
1.53–1.67). Study quality was low and the type of gene therapy
did not account for differences in outcome. Study design character-
istics accounted for a significant proportion of between-study het-
erogeneity.We observed similar findings in a data subset limited to
the most common gene therapy.
Conclusion: As the dysregulation of key molecular pathways is
characteristic of gliomas, gene therapy remains a promising
treatment for glioma. Nevertheless, we have identified areas
for improvement in conduct and reporting of studies, and we
provide a basis for sample size calculations. Further work should
focus on genes of interest in paradigms recapitulating human dis-
ease. This might improve the translation of such therapies into
the clinic.
Keywords: systematic review, rodent models, glioma, gene therapy
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Introduction
The prognosis for patients with malignant glioma remains
poor despite extensive experimental and clinical research.1
The most effective treatments tested in randomized
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controlled trials show a median survival of 14 months from
diagnosis,2 only marginal progress from the 9 months
median survival reported in clinical trials in the 1970s.3,4 This
poor prognosis reflects the highly invasive nature of malig-
nant glioma and resistance to conventional anticancer treat-
ments.5–7 These tumours are proliferating lesions within an
otherwise quiescent organ and rarely metastasize, rather
progressing by diffuse invasion along white matter tracts
and by inducing oedema through generation of abnormal
blood vessels.8 Therefore they are an ideal target for local
gene therapy, as such genes can be designed to target mitotic
cells,9,10 providing a basis for cell-selective cytotoxic therapy.
Similarly, genes can be designed and introduced to modulate
key processes in glioma growth and the body's response to it,
such as angiogenesis and the host immune response—bothof
which play a key role in disease progression.11,12
However, as is the case in many areas of biomedical
research, the promising results frompreclinical animalmod-
els have failed to be translated effectively into the clinic.13–15
This is exemplified by twounsuccessful phase III randomized
controlled trials of gene therapy16,17 and variable responses
in other smaller clinical studies.6,18–21
Several narrative reviews have described the promise of
gene therapy in malignant glioma7,22–24; however, thus far
this promise has remained unfulfilled in the clinical setting.
Three complementary reasons for this failure have been
proposed: (1) efficacy is overstated in animal models, (2)
potential efficacy is understated in human clinical trials or
(3) animal models simply do not recapitulate the human dis-
ease with sufficient fidelity in order to be useful. Systematic
review and meta-analysis can provide a more transparent
and objective summary of a field of research than narrative
reviews; they allow assessment of scientific rigour of
included studies using standard instruments. In addition,
stratified meta-analysis can explore the impact of independ-
ent study design variables (termed external validity) on
reported outcome; assess the prevalence and impact of
measures to reduce bias such as randomization, blinded out-
come assessment and sample size calculations (termed
internal validity); and can provide evidence of possible pub-
lication bias—a phenomenon where comparative over-
reporting of small efficacious studies versus small ineffective
studies leads to a false overestimation of the benefit of a
given therapy.25,26 Several previous studies on experimental
models of neurological disease have demonstrated the flaws
in the internal validity of studies and have shown that report-
ing of such measures can significantly affect efficacy esti-
mates.15,27–29 Consequently, assessing these features
forms a critical domain of the systematic review and
meta-analysis in preclinical literature.
We hypothesized that limitations in the internal and
external validity in animal modelling lead to an overstate-
ment of efficacy of gene therapy in animal models of glioma.
Here we use systematic review and meta-analysis to
describe the relationship between study design, study qual-
ity and the reported improvements in median survival, and
the fidelity with which limitations in the animal data were
taken into account in the design of human clinical trials.
Methods
L I T E R A T U R E S E A R C H A N D I N C L U S I O N C R I T E R I A
Relevant full publications and meeting abstracts were
identified by electronic searching of three online databases
(Pubmed, Embase and Web of Knowledge) using the
search terms: <gene therapy> AND <<glioma> OR <brain
tumour> OR <brain tumour> OR <brain neoplasm>OR
<glioblastoma> OR <ependymoma>OR <astrocytoma>
OR <oligodendroglioma>>. Results were limited to animal
studies with no language or date limits. Following comments
raised in the review, we tested whether the term <gene
therapy> was overly restrictive by searching for <glioma>
and <thymidine kinase> to determine whether additional
studies would be identified.
The inclusion criteria were adapted from previously pub-
lished criteria30 and required studies to report: (1) a single
formof gene therapy, (2) a rat ormousemodel of glioma, (3)
the glioma cell line used, (4) intracerebral implantation of
the tumour, (5) median survival data reported within the
textorwhich could be calculated fromKaplanMeier survival
graphs and (6) the number of animals in the control and
treatment group(s). We defined a single gene therapy as
the use of a single vector containing either one or multiple
genes. To improve the sensitivity of identification of
relevant studies, each publication identified in the electronic
search was assessed individually against the inclusion and
exclusion criteria by two of four independent reviewers
(SC, ALM, TCH and MRM), with differences resolved by
discussion.
M E T H O D O L O G I C A L Q U A L I T Y
A 9-item quality checklist was adapted from the CAMAR-
ADES (Collaborative Approach to Meta-Analysis and
Review of Animal Data in Experimental Studies) published
criteria31 and the glioma-specific score previously described
by our group.30 The checklist comprised (1) publication in a
peer-reviewed journal and the reporting of (2) the number
of tumour cells implanted, (3) randomized allocation of
tumour-bearing animals to treatment and control groups,
(4) blinded assessment of outcome, (5) a sample size calcu-
lation, (6) compliance with animal welfare regulations, (7) a
potential conflict of interest, (8) the number of animals orig-
inally inoculated with tumour cells and (9) an explanation of
any treated animals excluded from survival analysis. While
not detailed as a quality checklist item in the study protocol,
in response to comments raised in reviewwe have also con-
sidered whether the study provided evidence of successful
transduction and gene expression in vitro, and whether the
study provided evidence of infection, replication and
expression in the tumour in vivo.
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D A T A E X T R A C T I O N A N D A N A L Y S I S
We extracted data for median survival time, the number of
animals in both the treatment and control groups and details
of study design characteristics (the gene therapy used, ani-
mal species, co-morbidities, tumour cell line, gene therapy
vector, route of administration, number of doses, delay to
treatment and method of determining survival and presen-
tation of data (i.e. textual or graphical)). We grouped gene
therapy into broad categories of angiogenesis, DNA repair,
immunomodulation, oncolytic and “other”. We calculated
an effect size for each comparison by dividing the median
survival in the treatment group by the median survival in
the control group to give a median survival ratio.
A preliminary stratification identified that studies that
used a prodrug in the treatment group (to activate the
gene therapy) but not in the control group were associated
with significantly larger effects than those using prodrug in
both groups, suggesting biological activity of the prodrug
alone. Therefore, studies using a prodrug were only
included where the same prodrug was also used in the
control group. Some studies reported more than one con-
trol group. We considered the most appropriate control
group to be the one that was most similar to the treatment
group, while offering no functional gene therapy, according
to a hierarchy that prodrug with non-functioning vector
was preferred to prodrug with saline, which was preferred
to prodrug only. Where a prodrug was not used, the hier-
archy was non-functioning vector in preference to saline-
only in preference to no treatment. For studies in which
more than 50% of animals survived till the end of the
experiment, we used the last time point at which survival
was reported to give a conservative measure of median
survival.
Individual study effect sizes were weighted by the
number of animals for that comparison, as there is no inher-
ent measure of variance available for median survival data.
Where a control group served more than one treatment
group we corrected the weighting of the study by dividing
the number of animals in the control group by the number
of treatment groups served. Effect sizes were calculated on
log-transformed data32 using the random effects model of
Dersimonian and Laird,33 as we expected significant heter-
ogeneity between experiments.We estimated the standard
error of the summary estimates from the inter-study vari-
ance (as described previously27,34).
We used stratified meta-analysis to estimate the signifi-
cance of differences between groups of studies by partition-
ing heterogeneity and using the χ2 distribution with n − 1
degrees of freedom (where n is the number of strata).
We performed stratified analyses on the complete dataset
that included all gene therapies reported. We also per-
formed analyses on a more homogenous subset of data that
consisted of only the most common gene therapy—herpes
simplex virus thymidine kinase activated by ganciclovir
(GCV). To allow for multiple comparisons (we performed
26 comparisons; 15 on the complete dataset and 11 on
the thymidine kinase subset of data) we adjusted our signif-
icance level to p < 0.0019 using Bonferroni correction for
26 tests of statistical significance in the same dataset. We
used funnel plotting,35 Egger regression36 and “trim and
fill”37 to assess for the presence of publication bias.
To estimate the statistical power of a typical experiment,
we calculated the median observed values for median sur-
vival in the control and treatment groups and the median
numbers in each group and used the “stpower exponential”
functional in Stata. Data extracted from studies included in
the review and the results of meta-analysis and publication
bias assessment are available from the Dryad Digital Repos-
itory: http://doi.org/10.5061/dryad.bs8c4.38
Results
We identified 3,860 publications, of which 208 met our
inclusion criteria (Figure 1; Appendix S1, Supporting Infor-
mation). Of these, 193 publications reported data suitable
for meta-analysis; these described 427 comparisons using
6,366 animals (Appendices S1 and S2).
Overall, 127 different gene therapies were tested. A total
of 101 used a single gene and 26 used two genes in a single
vector (Appendices S2 and S3). Thymidine kinase was the
most common gene therapy (61 comparisons, given as a sin-
gle gene therapy in 49) followed by IL-4 (23 comparisons),
IL-2 (21 comparisons) and tumour necrosis factor-related
apoptosis inducing ligand (TRAIL, 18 comparisons). Across
all 127 gene therapies therewas a significant improvement in
the median survival time (survival ratio 1.60, 95% CI
1.53–1.67), and there was significant between-study heter-
ogeneity (χ2 = 1,522; df = 426, p < 0.0019; I2 = 72%). While
Figure 1. Study selection summary.
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the approaches to gene therapywere diverse, the broad cat-
egory of gene therapy used did not account for a significant
proportion of the observed heterogeneity (Figure 2).
R I S K O F B I A S
The median number of quality checklist items reported was
three of a possible nine (interquartile range (IQR) 3–4;
Appendix S4); 193 (100%) publications were in peer-
reviewed journals, 170 (88.1%) reported the number of
tumour cells implanted, 23 (12.4%) randomly allocated ani-
mals to group, 7 (3.6%) blinded the assessment of outcome,
133 (68.9%) had a statement of compliance with animal wel-
fare regulations, 15 (7.8%) had a statement of a potential
conflict of interest, 24 (12.4%) reported the number of ani-
mals originally inoculated with the tumour and 41 (21.1%)
gave an explanation of any treated animals excluded from
the survival analysis. A total of 139 studies (72.0%) provided
evidence of successful transduction and gene expression
in vitro and 90 (46.6%) provided evidence of infection, rep-
lication or expression in the tumour in vivo. No publication
reported a sample size calculation and themedian number of
animals in each of the control and treatment groups was
eight (IQR 6–10). In 90 publications it was reported that ani-
mals were killed when they manifested signs reflecting dis-
ease of a certain severity (rather than allowing them to
die of their disease), and in the remainder of studies the cir-
cumstances of death (euthanasia or spontaneous) were not
reported.
The aggregate number of quality checklist items scoredor
the reporting of randomized group allocation did not
account for between-study heterogeneity (Figure 3A). Only
seven publications (9/427 comparisons) reported the
blinded assessment of outcome, too few to allow further
analysis. We did not identify any differences in treatment
effects between studies that reported survival data within
the text and those where data were extracted from a graph.
Bias introduced by an excess of small, imprecise studies
was suggested with asymmetry in the funnel plot
(Figure 3B) and Egger regression (11.3 ± 0.301; t = 11.3,
p < 0.001; Figure 3C) but not using “trim and fill”.
I N F L U E N C E O F F A C T O R S R E L A T I N G T O G E N E
D E L I V E R Y
The method of gene delivery (molecules, viruses, cells or
virus-producing cells) had a significant impact on the
Figure 3. External validity. A. Stratification by aggregated quality score did not account for between-study heterogeneity, implying no
variation in efficacy with quality score in this dataset (p > 0.0019). The grey band represents global 95% confidence intervals (CIs);
columns represent mean ± 95% CI and column width a measure of number of comparisons within each stratum. The solid line represents
the level of neutral treatment effect. B. Funnel plots showing effect size (x-axis) versus a measure of study precision (y-axis). The dataset
appears to be skewed, with imprecise studies generally showing more efficacy than those with larger sample sizes. The solid line
represents the line of neutral treatment effect and the dotted line marks the global efficacy estimate. C. Egger regression plot depicting
effect size × precision (x-axis) versus precision (y-axis). Regression revealed a positive intercept (p < 0.001) implying an excess of small,
imprecise studies. The vertical solid line represents the level of neutral treatment effect; dotted lines represent 95% CI of the regression.
Figure 2. Stratification by gene therapy group. Grouping gene
therapies into those using a single gene or those using multiple
genes in a single vector did not account for between-study
heterogeneity (p > 0.0019, n = 387 and 40 respectively; black
plots with bold labels). Furthermore, subcategorizing the single
gene group by the broad mechanism of action of that gene did
not account for between-study heterogeneity (p < 0.0019, grey
plots). Plots represent mean ± 95% confidence interval (CI) and
the diamond represents a measure of number of comparisons
within each stratum. The dotted line represents the level of
neutral treatment effect.
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reported effect size. Cells and virus-producing cells were
associated with the largest treatment effects (χ2 = 24.1,
df = 3, p < 0.0019; Figure 4A). Furthermore, the selection
of viral delivery system accounted for a significant propor-
tion of between-study heterogeneity (χ2 = 53.0, df = 3,
p < 0.0019). The greatest estimates of effect were observed
where retroviruses and adeno-associated viruses were
used. Similarly, selection of cellular delivery system also
accounted for significant between-study heterogeneity
(χ2 = 56.2, df = 5, p < 0.0019). Bone marrow-derived stem
cells and neural stem cells were associated with the largest
effect sizes.
Several gene therapy paradigms were reported that usu-
ally included the concomitant use of a prodrug;
67 comparisons reported such combinations, for instance
thymidine kinase with GCV, cytosine deaminase (CD) with
5-fluorocystine (5-FC). Furthermore, these same gene
therapies were sometimes used without the appropriate
prodrug (35 comparisons). Gene therapies using a prodrug
were associated with an increased effect size if that prodrug
was used (1.90; 95% CI 1.67–2.14, n = 67) when compared
with the same gene therapies where no prodrug was used
(1.27; 1.14–1.41, n = 35; χ2 = 45.6, df = 1, p < 0.0019) with
median survival ratio being 50% higher (95% CI 35 –65%).
A further 17 comparisons involved prodrugs not usually
associated with the gene therapy used (i.e. prodrug used
alongside that gene in fewer than 50% of comparisons; e.g.
interferon with 5-FC, tumour necrosis factor with GCV).
Figure 4. Features of gene therapy delivery. A. The vector used to deliver gene therapy accounted for a significant proportion of
heterogeneity in the complete dataset, and there was evidence of differing efficacy between different cellular and virus vector
paradigms (p < 0.0019). The grey band represents global 95% confidence intervals (CIs); plots represent mean ± 95% CI and the
diamond represents a measure of number of comparisons within each stratum. The dotted line represents the level of neutral
treatment effect. B. The number of doses accounted for between-study heterogeneity (p < 0.0019), the largest effect seen with five
doses. The grey band represents global 95% CIs; columns represent mean ± 95% CI and column width a measure of number of
comparisons within each stratum. The solid line represents the level of neutral treatment effect. C The route of gene therapy delivery
accounted for heterogeneity, with the largest efficacy associated with intra-arterial and intraperitoneal systemic delivery, and ipsilateral
and contralateral intracranial therapy (p < 0.0019). There was no observed difference in efficacy between intracranial and systemic
administration. The grey band represents global 95% CIs; plots represent mean ± 95% CI and the diamond represents a measure of
number of comparisons within each stratum. The dotted line represents the level of neutral treatment effect. D. The delay to
treatment (where “0” refers to the day of tumour inoculation, “>0” therapy initiation post-tumour inoculation and “<0” therapy
initiated before tumour inoculation) accounted for heterogeneity (p < 0.0019), with therapy given concomitantly with tumour
inoculation giving the greatest efficacy. The grey band represents global 95% CIs; columns represent mean ± 95% CI and column width
a measure of number of comparisons within each stratum. The solid line represents the level of neutral treatment effect.
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Themost commonly used prodrugswereGCV (40 compar-
isons) and 5-FC (24 comparisons, see Appendix S2).
The number of gene therapy doses administered (ranging
from 1–7 doses) also accounted for a significant proportion
of the between-study heterogeneity. We observed a direct
relationship between the number of doses and effect size
where up to five doses were given followed by a fall in effi-
cacywhere six or sevendoseswere administered (χ2 = 50.1,
df = 6, p < 0.0019; Figure 4B). Intracranial gene therapy
delivery was common (328/427 comparisons) and we stra-
tified these into intratumoural, ipsilateral (gene therapy
introduced into the same cerebral hemisphere as the
tumour), contralateral (opposite hemisphere), coinocula-
tion (tumour and vector inoculated together), pretransfec-
tion (glioma cells transfected before tumour inoculation)
and unspecified intracerebral. While these groups contain
information on both location and time of implantation, we
used a single stratification as the variables display colinearity
(i.e. coinoculated cells can only be implanted at the same
time as the tumour, intratumoural injection requires an
established tumour to be present). Of these routes, intratu-
moural was the most common (226/328), followed by coin-
oculation (36/328) and pretransfection (31/328). The
remaining comparisons, except for one unknown, were
systemic—themost commonly used routes being subcutane-
ous (49/98) and intravenous (32/98). Therewas no difference
in observed effect size between treatments that were deliv-
ered centrally and those that had to cross the blood–brain
barrier (delivered systemically); however,wedid observe sig-
nificant portion of heterogeneity accounted for by more
specific stratification of route of delivery (χ2 = 45.0, df = 11,
p < 0.0019; Figure 4C). The routes associated with greatest
efficacy were ipsilateral and contralateral central delivery,
which were more effective than intratumoural treatment.
Gene therapy was delivered from 1month before to 1
month after tumour induction. We stratified the data into
three groups (before, the same day as, or after the induction
of tumour), and the timing of treatment had a significant
impact on reported efficacy (χ2 = 13.0, df = 2, p < 0.0019;
Figure 4D). Where tumour cells were treated in vitro prior
to implantation these were classified as therapy starting on
the sameday as implantation. The typeof control groupused
did not account for any between-study heterogeneity.
I N F L U E N C E O F F A C T O R S R E L A T I N G T O T H E
A N I M A L M O D E L U S E D
Overall, studies using rats reported significantly higher
effect sizes (1.71; 95% CI 1.58–1.86; n = 144) than mice
(1.54; 1.46–1.63; n = 283; χ2 = 13.0, df = 1, p < 0.0019;
Figure 5A). Experiments were carried out in animals with
no reported alterations of their immune status (310/427),
athymic animals (92/427) and animals with various forms
of severe combined immunodeficiency (SCID; 25/427);
studies using SCID animalswere associatedwith greater effi-
cacy (χ2 = 16.2, df = 2, p < 0.0019; Figure 5B). Although the
species of origin of the tumour line (mouse, rat, human or
unknown) did not account for any between-study heteroge-
neity, we observed an effect of the tumour line itself (χ2 =
244, df = 38, p < 0.0019; Figure 5C).
Median survival across all control groups was 25 days and
across all treatment groups was 40 days. With a median of
eight animals in control and treatment groups we estimate
that the median powered study in this cohort has only 17%
statistical power to detect themedian change inmedian sur-
vival. This compares with around 30% in experimental
stroke studies (CAMARADES group, data not published),
and a convention of seeking power of 80 to 90% in well-
conducted clinical trials. As a guide for future investigators
in Appendix S5, we present the relationship between statis-
tical power and number needed per group for the above
comparison and for a range of median survival ratios that
might be sought for in future experiments.
T H Y M I D I N E K I N A S E D A T A S E T S U B - A N A L Y S I S
We performed a sensitivity analysis for the most common
gene therapy paradigm (thymidine kinase with GCV,
30 comparisons using 446 animals). Thymidine kinase gene
therapy was associated with a significant increase in median
survival (1.99; 95% CI 1.68–2.37) and between-study heter-
ogeneity comparable with the complete dataset (χ2 = 49.9,
df = 29, p < 0.0019; I2 = 69%).
The risk of bias appears to be similar between the two
datasets. The median study quality score was again 3 (IQR
2–3.25) andwedid not find an association between the num-
ber of study quality checklist items scored and efficacy
(Figure 6A). Small study bias was suggested with asymmetry
in the funnel plot and a positive intercept on Egger regres-
sion (11.56 ± 1.76; t = 6.61, p < 0.001; Figure 6B and C),
but not in “trim and fill” analysis. Again, there were no dif-
ferences between studies that reported survival data within
the text and those where data had to be extracted from a
graph, or between the types of control used.
Only one study usedmore than one dose of gene therapy,
only three used a route of delivery other than intracranial
inoculation and only three reported efficacy in animals with
co-morbidity; these data were not analysed further. There
was noeffect of themethodof genedelivery, the vector used
(Figure 6D), the time to delivery, the species used or the
species of origin of the tumour cell line.
The tumour line itself did however account for some of
the observed heterogeneity in this dataset (χ2 = 40.4, df =
7, p < 0.0019; Figure 5E), as did the approach to determining
survival (euthanasia, spontaneous death, unreported) (χ2 =
24.4, df = 2, p < 0.0019),with largest effect observed in stud-
ies reporting spontaneous death (median survival ratio 8%)
(95% CI 1–15%) higher compared with studies killing ani-
mals when they became symptomatic).
Searching for <glioma> and <thymidine kinase> identi-
fied only one additional study. In a sensitivity analysis
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including data from this study, therewere no changes of sub-
stance either in the point estimates of efficacy or in any of the
conclusions drawn.
Discussion
In this first systematic review andmeta-analysis of gene ther-
apy in experimental glioma we show substantial and signifi-
cant prolongation of median survival across a range of
experimental conditions. However, there is a high risk of
bias in included studies and we observed substantial heter-
ogeneity; consequently these results should be interpreted
with caution. We observed influences on reported efficacy
by vector type, control type, delay to treatment, glioma
model selection, animal, immune status and the method
of determining survival. Further high-quality preclinical
investigation developed to better define the impact of the
study design characteristics listed above, and in particular
for those in which we identified substantial efficacy in con-
ditions that reflect those seen in humandisease,may provide
promising avenues for clinical trial development.
S T U D Y Q U A L I T Y
Overall the quality of studies was limited; the median num-
ber of quality checklist items scored was three of a possible
nine (IQR 3–4). Our threshold for significance testing was
conservative (Bonferroni correction for 26 stratifications),
and while testing for an effect of study quality on treatment
efficacy did not reach this significance threshold (p = 0.024),
an association is likely. Only 12% of studies reported ran-
domization and less than 4% reported the blinded assess-
ment of outcome. As two thirds of studies met either
Figure 5. Glioma model setup.A. Gene therapy in rats was associated with greater efficacy than in mice (p < 0.0019). B. Immune status
was associated with heterogeneity: use of animals with severe combined immunodeficiency were associated with greater efficacy than
athymic or normal counterparts (p < 0.0019). The grey bands represent global 95% confidence intervals (CIs); columns represent
mean ± 95% CI and column width a measure of number of comparisons within each stratum. The solid line represents the level of
neutral treatment effect. C. Glioma model was associated with between-study variance (p < 0.0019), with greatest efficacy seen with
N32 and G203 lines in the complete dataset. Furthermore, the species of tumour origin was associated with heterogeneity (p <
0.0019). The grey band represents global 95% CIs; plots represent mean ± 95% CI and the diamond represents a measure of number
of comparisons within each stratum. The dotted line represents the level of neutral treatment effect.
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three or four checklist items and none met more than
seven, we have not been able to ascertain whether high-
quality studies give lower estimates of efficacy. This con-
trasts with findings from other models of neurological dis-
ease, where the prevalence of reporting of such factors is
higher and where there is evidence that high-quality studies
report lower estimates of efficacy.15,39,40 We found some
evidence of publication bias, including a positive intercept
using Egger regression, but the trim and fill approach did
not impute any theoretical missing studies. It has been sug-
gested that trim and fill is less powerful than Egger
regression,36 but the small study effects detected by Egger
regression may have other causes, particularly where there
is substantial heterogeneity between studies, as is the case
Figure 6. Thymidine kinase/HSV-1with ganciclovir (GCV) subset analysis.A. Stratification by aggregated quality score did not account for
between-study heterogeneity (p > 0.0019). The grey band represents global 95% confidence intervals (CIs); columns represent mean ±
95%CI and columnwidth ameasure of number of comparisonswithin each stratum. The solid line represents the level of neutral treatment
effect. B. Funnel plots showing effect size (x-axis) versus a measure of study precision (y-axis). The dataset appears to be skewed, with
imprecise studies generally showing more efficacy than those with larger sample sizes. The solid line represents the line of neutral
treatment effect and the dotted line marks the global efficacy estimate. C. Egger regression plot depicting effect size∗precision (x-axis)
versus precision (y-axis). Regression revealed a positive intercept (p < 0.001). The vertical solid line represents the level of neutral
treatment effect; dotted lines represent 95% CI of the regression. D. The vector used to deliver gene therapy was not associated with
between-study heterogeneity (p > 0.0019). E. The tumour line used accounted for heterogeneity (p < 0.0019), with RSV-M, BT4C and
C6 lines associated with greatest efficacy. However, we observed no difference in efficacy between cells originating from different
species (p > 0.0019). The grey bands in D–E represent global 95% CIs; plots represent mean ± 95% CI and the diamond represents a
measure of number of comparisons within each stratum. The dotted line represents the level of neutral treatment effect.
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here.41Our findings are consistent with the presence of pub-
lication bias of the same order as reported in a previous sys-
tematic review of temozolomide in experimental glioma.27
S T U D Y D E S I G N F E A T U R E S A F F E C T I N G
E X T E R N A L V A L I D I T Y
We found no differences between broad categories of gene
therapies so we analysed all therapies together, with a sen-
sitivity analysis using only the most commonly used therapy.
It is likely that certain individual therapies were substantially
more or less effective than the overall estimate but 79% of
these were tested in fewer than four experiments
(Appendix S3), and in these circumstances meta-analysis
contributes little that cannot be gleaned from an examina-
tion of primary data. Nonetheless, thymidine kinase was
more efficacious than average (median survival ratio 1.99
vs. 1.60). While this supports there being differences in
efficacy between treatments there are alternative
explanations—for instance differences in the animal and gli-
oma models used. We found differences in efficacy associ-
ated with different vector-delivery mechanisms, routes of
gene therapy delivery, numbers of doses and delays to treat-
ment. Delivery of gene therapy using stem cells was associ-
ated with greatest efficacy in both datasets, and this might
relate tomoreeffective delivery to the required site of action,
more sustained gene expression or other factors. In the com-
plete dataset, intracranial delivery (rather than intralesional)
and multiple dosing (particularly four or more doses) were
most effective. In contrast to the difficulties of transfecting
tumours in humans with glioma, we were surprised that,
taken together, systemic therapies were as efficacious as
those delivered intracranially.42,43Over 90%of the thymidine
kinase studies administered gene therapy intracranially with a
single dose—analogous to clinical practice.16,44–46
We also found that features of the disease models used
were widely variable and significantly affected the observed
efficacy. A total of 40 different glioma cell lines were used,
originating from humans, mice and rats. No studies used
mice with spontaneously occurring or induced glioma cells
and only one reported the use of cells recently extracted
from human glioma specimens. Median survival ratios for
different cell lines ranged from 1 to 8.56 (median 1.57;
IQR 1.34–1.71). This suggests that cell line selection is
one of the most important factors for investigators to con-
sider during experimental design. As prominent were the
species used and their immune status. Rats and mice were
used in both datasets, and roughly one third of the animals
used were immune-suppressed; this was associated with
greater efficacy. The immune systemplays an important role
in the body's response to glioma, so the immune-
compromised mouse may not be an ideal model of human
disease.
Consistent with the modelling of other neurological con-
ditions, these data suggest that the efficacy of gene therapies
in glioma is characterized by heterogeneity in both the dis-
ease model used and the treatment delivery. Further, we
observed a low prevalence of reporting of measures to
reduce the risk of bias (seeAppendix S4 for details), possible
overstatement of efficacy in studies at risk of bias, and pub-
lication bias.15,29,40,47–49
P O T E N T I A L W E A K N E S S E S O F O U R A P P R O A C H
There are a number of potential weaknesses to this
approach. Foremost, meta-analysis is essentially an observa-
tional technique. When we stratify by various study design
characteristics and measures of study quality or bias, it may
be that there are other unknown differences that are the
cause of observed differences. For this reasonwe have been
rigorous in only investigating sources of heterogeneity that
we prespecified in a protocol. Our findings demonstrate
association rather than causality; the observation that treat-
ments delivered using cellular vectors are more effective
than those using viruses or molecular approaches may be
due to differences in gene delivery efficiency between these
routes, or alternatively itmay be that different types of inter-
ventions are more suited to different vector systems, and
that these interventions differ as a class in their efficacy,
or a difference in other study design characteristics shown
to be associated with heterogeneity. For this reason our
findings should be considered hypothesis-generating only.
However, further high-quality preclinical studies can be
used directly to test any hypothesis of interest.
Secondly, summarizing a field of research (as we have
attempted here) requires by necessity the combination of
data fromexperiments that are, to a greater or lesser extent,
dissimilar. In these circumstances, themeaning of a summary
estimate of efficacy across a range of studies has limited rel-
evance other than to provide a yardstick of themagnitude of
effect that might be expected of an intervention. However,
we believe the statistical explanation of the differences
between studies, especially in the face of the substantial het-
erogeneity observed here, is valid and important. This
rationale is the basis on which we have deemed it appropri-
ate, corroborated by the evidence that broad groups do not
differ in efficacy, to collate all gene therapies into a single
analysis—following this, heterogeneity was accounted for
by measures of study design rather than the gene therapy
paradigm itself. In support of these findings, we ran a sepa-
rate analysis on the most commonly used gene therapy par-
adigm, thymidine kinase with GCV; in general we found that
the same factors relating to study design and internal and
external validity of these experiments had a significant
impact on efficacy. Given the presence of such diversity in
study design, our findings on study quality, randomization,
controlling, experimental design and the consistency of
these between the two datasets provide validation of our
approach.
Our findings are only as reliable as the data on which they
are based, and we have shown that this is likely to be
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confounded by poor study quality and by publication bias.
However, our search strategy was broad, accepting confer-
ence abstracts and publications in languages other than Eng-
lish, so our approach is likely to provide a better summation
of what is known than narrative reviews—which are subject
to the same potential biases—and the impact of selection
bias is likely to have reduced to the minimum possible.
We used the term “gene therapy” in our search rather
than detailing specific genes so that we might identify the
largest number of studies, not just those where the use of
that gene was already widely known. The term “gene ther-
apy” may have been unduly restrictive, but searching for
“thymidine kinase” and “glioma” in Pubmed—without fur-
ther limitations—identified only one additional study, inclu-
sion of data fromwhich had no impact on the overall efficacy
estimate of efficacy. Finally, we have attempted to minimize
false positives in our statistical tests by adjusting for multiple
comparisons.
The use of meta-analysis to summarize median survival
data is not well established. Because we did not have access
to data for individual animalswe could not pool hazard ratios
as has been suggested for clinical studies,50 and instead have
used methods reported previously,27,34 based on the work
of Simes et al.,32 as a summary estimate that is comparable
with hazard ratio pooling.
W I T H I N T H E S E L I M I T A T I O N S , A R E T H E R E A N Y
I M P L I C A T I O N S F O R F U T U R E R E S E A R C H O R F O R
T H E D E S I G N O F C L I N I C A L T R I A L S ?
In this systematic review and meta-analysis, we have pre-
sented substantial evidence that features relating to the risk
of bias and experimental design of animal studies significantly
affect the observed efficacy of gene therapy for experimen-
tal glioma. However, another issue yet to be addressed is
that of construct validity; there is evidence from these data
that translation of gene therapy from experimental to clin-
ical glioma has failed because the experimental models do
not recapitulate human disease.
The optimized conditions that are generally created for
animal studies do not recapitulate the heterogeneity of
human glioma patients, as these studies are all undertaken
on homogeneous rodent populations. While techniques
such as meta-analysis seek to counteract this homogeneity,
the breadth achieved still does not reflect that of the human
population. For example, of these animals, many are
immune-compromised, a feature that is uncommon in clin-
ical practice. We have observed a wide variety of glioma
models used, but those most commonly selected (GL261,
U87 and C6) tend to grow quickly and relatively non-
invasively into large discreet spheres,51,52 contrasting
sharply with irregularly shaped, poorly defined, infiltrative
human glioblastomamultiforme tumours.1,8While each cell
line has certain properties that do relate to human disease—
for example extensive capillary networks in U87 models,53
whitematter invasionand lowimmunogenicity inGL261,54–56
gene mutations in C6 that are comparable to human gli-
oma57—these tumours are appropriate for the study of par-
ticular components of glioma biology (such as angiogenesis
in U87 or immune therapies in GL261) but perhaps lack the
robustness for survival studies preceding translation into
clinical trial. The recent emergence of the glioma stem cell
hypothesis (implicating a cell with stem-like features in the
aetiology and pathogenesis of human glioma) has influenced
the design of novel preclinical models,58 but these, to our
knowledge, have not yet been adopted into animal studies
of gene therapy. Another novel practice is the use of
patient-derived xenografts, where animals are inoculated
with tumour cells prepared from fresh human surgical speci-
mens rather than cells from established in vitro cultures.
These models may be more characteristic of human disease
and provide genetic heterogeneity not seen with traditional
glioma models;59 however, we identified only one relevant
study using this approach. Finally in animal studies gene
transfection rates are evidently high enough to be therapeu-
tic, even when vectors are delivered systemically. Indeed,
GL261 tumours are transfected very efficiently by adeno-
viruses.60 This contrasts with human therapy where trans-
fection rates are low; the blood–brain barrier is obstructive
in glioma therapeutics, preventing the useof systemic vector
delivery,43,61 even when vectors are delivered distal to the
ophthalmic artery (Dr Robin Grant, personal communica-
tion), as tumour penetration is poor and side effects high.
When implanted locally, distribution throughout the
tumour is difficult to achieve.43 This may be attributable
to differences in the central nervous system anatomy and
the host immune system.43
The large between-study heterogeneity observed in our
data suggests that the efficacy of gene therapy is very varia-
ble, depending at least in part on the features we have
described and perhaps to a greater degree than is observed
in other glioma treatments.27,30 This matches the so-called
lack of “robustness” seenwith gene therapy in phase II and III
clinical trials42 that has ultimately led to failure.
The statistical power of the experiments included in this
meta-analysis was low, and no study reported a formal sam-
ple size calculation. Improving the statistical power of gene
therapy experiments may help to reduce heterogeneity by
reducing the chances of type II (false negative) errors and
also the predictive value of positive studies where the prior
probability of success was low.62,63 We hope the commu-
nity finds our guide to statistical power (Appendix S5) help-
ful in the design of future experiments.
In spite of these limitations, gene therapy treatment for
experimental glioma appears to be effective when initiated
at later time points, and efficacy was observed against cells
of human origin. Both these features are pertinent to suc-
cessful treatment for human disease, as tumours are only
discovered after a period of growth. Gene therapy was
effective when given either intracranially or systemically
although this does not seem to correlate with clinical
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experience. Efficacy appeared to be highest when five doses
of the gene therapy were given, but—given the difficulties of
systemic administration in humans—it may not be practica-
ble to implant locally more than once. Exploration of the
most effective number of treatments was not addressed
in any of the included publications and is an important topic
for further animal study.
As such, we recommend that future preclinical research
focuses on genes ratified in both animal and human glioma
cell biology, using orthotopic tumours and intracranial gene
delivery over one or more doses; they should ideally use
stem-like cancer cells or patient-derived xenografts, or at
least provide a rationale for tumour model selection, in
non-immune-compromised animals where possible. These
studies should be registered, randomized, blind assessment
of outcome and provide a sample size calculation in all but
hypothesis-generating experiments in accordance with
ARRIVE guidelines.64
Conclusions
Gene therapies are associated with substantial increases in
median survival in animal models of cerebral glioma, but
because of concerns about the internal (study quality),
external (study design) and particularly construct (recapit-
ulation of human disease) validity of this literature, these
findings should be interpreted with caution. Our analysis
suggests that a strategy based on multiple treatments with
viral or cellular vectors expressing genes of interest deliv-
ered locally, tested in the potentially more relevant tumour
models described recently, represents a plausible approach
to developing gene therapies for glioma. However, the
issues of study quality and construct validity of existingmod-
els that we have identified here should be addressed in fur-
ther animal studies if such strategies are to have the best
chance of success.
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